Nanoscope Therapeutics to Present Groundbreaking Data at the 2025 ASRS Annual Meeting

Nanoscope Therapeutics to Unveil Key Data at the 2025 ASRS Annual Meeting

Nanoscope Therapeutics Inc., an innovative biotechnology company, is set to present pivotal findings at the upcoming 2025 American Society of Retina Specialists (ASRS) Annual Scientific Meeting. This event is scheduled to take place from July 30 to August 2, 2025, at the Long Beach Convention Center in Long Beach, California. The presentation will revolve around the compelling 126-week results from the RESTORE follow-up study (REMAIN), which focuses on the efficacy and safety of Nanoscope’s leading optogenetic therapy, MCO-010, designed to treat Retinitis Pigmentosa (RP).

Overview of MCO-010 and Its Significance

MCO-010 is part of Nanoscope’s multi-characteristic opsin (MCO) gene therapy platform aimed at addressing the needs of patients suffering from severe vision loss caused by inherited retinal diseases. This therapeutic approach is unique due to its gene-agnostic nature, allowing for treatment without prior genetic testing, thereby broadening its applicability among RP patients.

Dr. David S. Liao, a retina and vitreous disease specialist with Retina-Vitreous Associates Medical Group, will detail the robust safety and efficacy profile of MCO-010 during the session titled 'Extended Efficacy and Safety of MCO-010 Optogenetic Therapy for RP 126-Week Results From the RESTORE Follow-Up Study (REMAIN)'. This presentation is part of the Hereditary Retinal Disease Genetics Symposium 1 and is scheduled for Friday, August 1, at 4:50 PM PDT.

Presentation Highlights

During the session, Dr. Liao will discuss the significant findings from the REMAIN study, emphasizing the positive safety and efficacy outcomes after a 126-week treatment period. This data is particularly crucial as Nanoscope has recently initiated a rolling submission of a Biologics License Application (BLA) to the FDA for MCO-010, targeting severe vision loss due to RP. The timeline for FDA review is eagerly anticipated by the retinal disease community, as it could lead to an innovative treatment option for patients who currently have limited choices.

Dr. Samuel Barone, the Chief Medical Officer at Nanoscope, expressed enthusiasm about the presentation, stating, "We are excited to have this 126-week data presented at ASRS, especially with our recent BLA announcement. This will be a great opportunity for the ASRS community to discuss our data and its potential impact on RP patients." Such statements underline the relevance of this event for healthcare professionals dealing with retinal diseases.

Expanding Frontiers in Gene Therapy

Nanoscope’s dedication goes beyond treating Retinitis Pigmentosa. The company is also exploring a host of other retinal degenerative conditions. For instance, they have recently posted positive results from their STARLIGHT Phase 2 clinical trial, which involved MCO-010 in Stargardt disease (SD). Plans are underway to initiate a Phase 3 registrational trial in 2025 for this indication as well. MCO-010 has additionally received FDA Fast Track and Orphan Drug designations for both RP and SD, indicating its potential as a transformative therapy in the ocular field.

As an innovator in biotechnology, Nanoscope Therapeutics embodies the spirit of progress in medical research, significantly enhancing the horizon for patients impacted by retinal diseases. Their efforts are a testament to the commitment in providing groundbreaking solutions that can restore vision and transform lives.

For further inquiries about MCO-010 or to learn more about Nanoscope Therapeutics, visit their official website at www.nanostherapeutics.com.